Boehringer-Ingelheim's intravenous Spevigo (spesolimab) is a therapy specifically indicated to treat active Generalized Pustular Psoriasis (GPP) flares. Nearly 90% of dermatologists with prior use reported spesolimab as very effective, according [...]
Drug development for homocystinuria is limited to just three clinical-stage products, two of which are injectable enzyme replacement therapies (ERTs). NEWTON, Mass., April 11, 2023 /PRNewswire/ -- Classic homocystinuria (HCU) is a [...]
Several companies including argenx, Sanofi/Regeneron, and AstraZeneca are seeking to improve Bullous Pemphigoid standard of care by pursuing label expansions for their existing antibody-based therapies. NEWTON, Mass., March 16, 2023 /PRNewswire/ -- Bullous [...]
AdComm experts were split on whether to approve Amgen's Tavneos (avacopan) in 2021, however, this sentiment has not been reflected in physician uptake and perception of Tavneos which has been [...]
According to REACH Market Research, dermatologists agree that Frontal Fibrosing Alopecia (FFA) is generally more difficult to treat, and less likely to have an optimal response to treatment than Alopecia Areata [...]
First-to-market Regeneron/Sanofi's Dupixent (dupilumab) sees strong uptake in Eosinophilic Esophagitis (EoE) since its May 2022 FDA approval, according to findings from REACH Market Research. NEWTON, Mass., Feb. 21, 2023 /PRNewswire/ -- Despite being recognized [...]